Rohto Pharmaceutical Co (JP:4527) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rohto Pharmaceutical Co. reports a significant sales increase in the first quarter of FY3/2025, spurred by the lifting of pandemic restrictions and a weaker yen, leading to higher operating and ordinary profits. However, net income fell due to extraordinary losses. The company saw growth across domestic, Asian, European, and American markets, with an upward revision of the full-year forecast and an increased annual dividend from 30 yen to 33 yen.
For further insights into JP:4527 stock, check out TipRanks’ Stock Analysis page.